Buyout chatter pushed shares of Shire plc (FTSE:SHP) up nearly 2% in London yesterday and added 1.4% on Wall Street.
Hologic
Birth control battle continues as Hologic appeals and Conceptus pursues injunction | Legal News
McKesson’s Q3 beats The Street, pays $918M for Canadian pharmacy biz | Earnings Roundup
McKesson (NYSE:MCK) shares got a bump in after-hours trading yesterday when it reported strong 3rd-quarter results and announced the $918 million acquisition of a chain of independent pharmacies in Canada.
Thoratec settles Oracle beef | Wall Street Beat
Thoratec Corp. (NSDQ:THOR) said it reached an agreement with one of its major institutional shareholders, Oracle Investment Management, over whether or not the heart pump maker should hire an investment bank to find a buyer.
Greenwich, Conn.-based Oracle, which holds a 5.2% stake in the heart pump maker, recommended that Thoratec retain an investment bank to explore strategic alternatives, including sale to a larger company.
MassDevice.com +3 | MassDevice Q&A with Medtronic CEO Omar Ishrak, Judge strikes down Conceptus’ injuction against Hologic and CMS blames economy for health care spending drop
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Judge strikes down Conceptus’ request for an injunction against Hologic
Bankers’ outlook grim for U.S. IPOs | Wall Street Beat
Bankers aren’t expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.
About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.
Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.
New Conceptus CEO expects boost from ACA | Wall Street Beat
The Affordable Care Act’s provision covering contraception could be an "inflection point" for Conceptus (NSDQ:CPTS) and its Essure female sterilization system, new CEO Keith Grossman told Leering Swann analysts last month.
FDA approves AtriCure’s Synergy cardiac ablation device | Regulatory Roundup
AtriCure (NSDQ:ATRC) shares got a modest bump today after revealing pre-market approval from the FDA for its Synergy radiofrequency ablation system for atrial fibrillation.
ATRC shares were up 2.1% to $10.86 as of about 1 p.m. today.
Conceptus names new CEO, lowers 2012 guidance | Personnel Moves
In a sudden switch, Conceptus (NSDQ:CPTS) named Keith Grossman president & CEO upon the resignation of Mark Sieczkarek, whose departure was announced on the heels of lowered sales guidance for 2012.
Sieczkarek’s resignation, after 7 years at the helm, was announced simultaneously with Grossman’s appointment. Grossman will join the company’s board of directors, from which Sieczkarek also resigned.
Abiomed hits 52-week high | Wall Street Beat
Abiomed (NSDQ:ABMD) shares hit $20.25 apiece yesterday, their highest mark in 52 weeks, as the company touted more positive study results for its flagship Impella heart pump.
ABMD shares closed yesterday at $20.14, up 6.2 percent on a day of widespread gains on Wall Street. The Dow Jones Industrial Average gained 4.2 percent yesterday, the S&P 500 closed up 4.3 percent and the Dow Jones medical device index rose 4.8 percent.